Evaluation of Serum TRACP-5b, BALP, and 25-Hydroxyvitamin D3 Levels in Stage III Periodontitis Patients
TRACP-BALP-D3
Evaluation of the Effects of Non-Surgical Periodontal Therapy on Serum TRACP-5b, BALP, and 25-Hydroxyvitamin D3 Levels in Patients With Stage III Periodontitis
1 other identifier
interventional
16
1 country
1
Brief Summary
Periodontitis is a chronic inflammatory disease characterized by the progressive destruction of the supporting tissues of the teeth. Non-surgical periodontal therapy is the first-line treatment approach and aims to control inflammation and prevent further tissue breakdown. The aim of this interventional clinical study is to evaluate the effects of non-surgical periodontal therapy on serum levels of tartrate-resistant acid phosphatase 5b (TRACP-5b), bone alkaline phosphatase (BALP), and 25-hydroxyvitamin D3 in patients diagnosed with Stage III periodontitis. Patients with Stage III periodontitis will receive non-surgical periodontal therapy consisting of scaling and root planing. Clinical periodontal parameters and blood samples will be collected at baseline and after treatment. Changes in serum biomarker levels before and after therapy will be analyzed to assess the relationship between periodontal treatment and bone metabolism-related biomarkers. The findings of this study are expected to contribute to a better understanding of the systemic biochemical response to periodontal therapy in patients with advanced periodontitis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Dec 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 5, 2024
CompletedFirst Submitted
Initial submission to the registry
December 22, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 15, 2026
CompletedFirst Posted
Study publicly available on registry
February 27, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
March 15, 2026
CompletedFebruary 27, 2026
February 1, 2026
1.1 years
December 22, 2025
February 23, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in Serum TRACP-5b Level
Change in serum tartrate-resistant acid phosphatase 5b (TRACP-5b) levels measured before and after non-surgical periodontal therapy.
Baseline (pre-intervention) and Month 2 post-treatment
Secondary Outcomes (4)
Change in Probing Depth (PD)
Baseline (pre-intervention) and Month 2 post-treatment
Change in Clinical Attachment Level (CAL)
Baseline (pre-intervention) and Month 2 post-treatment
Change in Plaque Index (PI)
Baseline (pre-intervention) and Month 2 post-treatment
Change in Gingival Index (GI)
Baseline (pre-intervention) and Month 2 post-treatment
Other Outcomes (2)
Changes in Serum 25-Hydroxyvitamin D Level
Baseline (pre-intervention) and Month 2 post-treatment
Change in Serum Bone Alkaline Phosphatase (BALP) Level
Baseline (pre-intervention) and Month 2 post-treatment
Study Arms (1)
Non-Surgical Periodontal Therapy
EXPERIMENTALParticipants with Stage III periodontitis receive non-surgical periodontal therapy consisting of scaling and root planing performed according to standard clinical protocols.
Interventions
Non-surgical periodontal therapy consisting of scaling and root planing performed using hand instruments and ultrasonic devices according to standard clinical protocols.
Eligibility Criteria
You may qualify if:
- Adults aged 18 to 65 years
- Diagnosed with Stage III periodontitis according to the current periodontal classification
- Systemically healthy individuals
- Presence of at least 20 natural teeth
- Willingness to participate in the study and provide written informed consent
You may not qualify if:
- Presence of systemic diseases that may affect periodontal status or bone metabolism
- Use of antibiotics, anti-inflammatory drugs, or medications affecting bone metabolism within the last 3 months
- Pregnancy or lactation
- Current smokers or history of smoking
- Previous periodontal treatment within the last 6 months
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Atatürk University Faculty of Dentistry
Erzurum, Erzurum, Turkey (Türkiye)
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
December 22, 2025
First Posted
February 27, 2026
Study Start
December 5, 2024
Primary Completion
January 15, 2026
Study Completion
March 15, 2026
Last Updated
February 27, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will not share
Individual participant data will not be shared due to patient confidentiality considerations and the single-center design of the study.